N/A N=9 Prevention

Suicide Prevention for Sexual and Gender Minority Youth (Case Series)

Suicide

Bottom Line

View on ClinicalTrials.gov: NCT04757649 ↗

Enrolled (actual)

Serious AEs

11.1%

Results posted

May 2023

Primary outcome: Primary: The Interpersonal Needs Questionnaire-15 (INQ-15) - Thwarted Belongingness — -0.29 Cohen's d effect size

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Safety Planning Intervention with Navigation Services (Behavioral)
Age: Pediatric, Adult · 15+ yrs
Sex: All
Sponsor: San Diego State University
Primary completion: Oct 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY The Interpersonal Needs Questionnaire-15 (INQ-15) - Thwarted Belongingness	-0.29	—
PRIMARY Suicide-Related Coping Scale (SRCS) - Internal Coping Skills	0.67	—
PRIMARY Suicide-Related Coping Scale (SRCS) - External Coping Skills	0.86	—

Summary

The overarching goal of this study is to develop a suicide prevention program for sexual-and-gender-minority youth and emerging adults. After development of the intervention program, a case series trial will be conducted to test the feasibility and acceptability of the intervention and study methods.

Eligibility Criteria

Inclusion Criteria

Age 15 to 29 years
Identifies as gay, lesbian, bisexual, transgender, genderqueer, asexual, pansexual, non-binary, or another non-exclusively heterosexual identity, and/or reports same-gender romantic attraction, and/or reports same-gender sexual behavior in the past 12 months
Resides in San Diego County, California
Speaks English
Is willing and able to provide informed consent
Reports suicidal ideation over the past two weeks, as indicated by the clinician-administered Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline version
Reports a lifetime history of one or more suicide attempts

Exclusion Criteria

Individuals with immediate intention to attempt suicide will be excluded.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04757649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.